ClinicalTrials.gg
CompletedNCT05598320ApproaCHUpdated Jul 14, 2026Results posted

A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Children With Achondroplasia

A Phase 2/3 interventional study of Navepegritide (TransCon CNP) and Placebo for Navepegritide (TransCon CNP) in Achondroplasia, sponsored by Ascendis Pharma Growth Disorders A/S. Completed at 10 sites in 7 countries. Open to participants aged 2 Years to 11 Years. Per ClinicalTrials.gov, last updated 2026-07-14.

Sponsored by Ascendis Pharma Growth Disorders A/S · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
2 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Achondroplasia with a site in United States — 8 open to participants now, 11 under way, 3 of them phase 3. Achondroplasia · United States.

Enrollment
8th of 20
84 · median 76
Started
2023
with 4 others
Phase 2/3
3 of 29
2 open now
Registered
21st of 29
by date
Lead sponsor
2 of 29
Ascendis Pharma Growth Disorders A/S

Among the 29 studies in Achondroplasia with a site in United States, this one is the 8th largest by enrollment of the 20 interventional ones that give a count, is one of 5 that started in 2023, is one of 3 in phase 2/3, and was the 21st registered.

Achondroplasia

47 studies on the registry are indexed under Achondroplasia; 13 are open to participants now.

Browse Achondroplasia studies →

Open to participants now

8 of the 29 studies in Achondroplasia with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 9 Achondroplasia studies recruiting now, 2 set no upper age limit and 7 stop at 75 or younger; 9 take children under 18; none take healthy volunteers.

This study: 2 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Achondroplasia with a site in United States, or all of them as a file.
02

Study summary

The purpose of this clinical trial was to evaluate efficacy and safety of once weekly subcutaneous (SC) doses of 100 µg TransCon CNP/kg compared to placebo on Annualized Growth Velocity after a 52-week randomized treatment period in children aged 2 to 11 years with genetically confirmed Achondroplasia. The double-blind, placebo-controlled treatment period was followed by an Open Label Extension (OLE) period of a 52-week duration.

03

Conditions studied

  • Achondroplasia

Browse trials for

04

Who can participate

Ages eligible
2 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written, signed of the parent(s) or legal guardian(s) of the participant, and as required by the institutional review board/human research ethics committee/independent ethics committee (IRB/HREC/IEC).
  • Male or female, between 2 and 11 years of age (inclusive) at the time of Screening.
  • Clinical diagnosis of Achondroplasia (ACH) with documented genetic confirmation available.
  • Able to stand without assistance.
  • Parent(s)/legal guardian(s) willing and able to administer weekly SC injections of Medicinal Product (IMP) and to follow the protocol.
  • At least six months of growth and disease history from ACHieve (TCC-NHS-01) trial or comparable growth and disease history available from medical records (pending confirmation by Medical Monitor).
  • Considered eligible based on the medical history, physical examination, and the results of vital signs, and clinical laboratory tests performed during the Screening period

Exclusion criteria

Exclusion Criteria:

  • Participation (i.e., signed ) in any interventional clinical trial before within 3 months prior to screening.
  • Closed epiphysis.
  • Known or suspected to the IMP or related products (trehalose, tris[hydroxymethyl]aminomethane, succinate, and mPEG).
  • Had a growth disorder or medical condition other than ACH that results in short stature or abnormal growth such as severe ACH with developmental delay and acanthosis nigricans (SADDAN), hypochondroplasia, growth hormone deficiency, Turner syndrome, pseudoachondroplasia, inflammatory bowel disease, celiac disease, hypothyroidism, hyperthyroidism, pre-diabetes, or diabetes mellitus.
  • Have received any dose of prescription medications and IMP or surgical intervention intended to affect stature, growth, or body proportionality at any time.
  • Required, or anticipated to require, chronic (> 4 weeks) or repeated treatment (more than twice/year and >3 weeks/year) with systemic during participation in the trial. Chronic use of high-dose inhaled corticosteroids was not allowed.
  • Known history of presence of injury or disease of the growth plate(s), other than ACH, that affects growth potential of long bones.
  • Known history of any bone-related surgery affecting growth potential of long bones, such as:

    • Orthopedic reconstructive surgery for bone lengthening (e.g., procedures for leg bowing such as 8-plate are not exclusionary).
    • Cervicomedullary decompression surgery without anticipated need for repeat decompression during the time of the trial are allowed with minimum of 6 months of bone healing.
    • Ventriculoperitoneal (VP) shunt and laminectomy with full recovery are allowed with minimum of 6 months of bone healing.
    • Bone fracture within 6 months prior to screening (within 2 months for fracture of digits and buckle fractures).
  • findings at Screening, such as:

    • Expected to require surgical intervention during participation in the trial. Common surgeries, such as insertion of grommets, adenoidectomy, tonsillectomy, or myringotomy tube placement, are permitted.
    • Severe untreated sleep apnea or newly initiated sleep apnea treatment (e.g., Continuous Positive Airway Pressure [CPAP] in the previous 2 months prior to Screening).
    • Musculoskeletal disease, such as Salter-Harris fractures or clinical and/or radiographic evidence of severe hip pathology, or
    • Otherwise, are considered by the Investigator and Medical Monitor to make a participant unfit to receive trial treatment or undergo trial related procedures.
  • Had evidence at Screening that were consistent with severe cervicomedullary junction compression based on clinical and/or radiologic findings that indicated immediate surgical intervention was required.
  • Had a clinically significant finding or arrhythmia as determined by the investigator in consultation with the medical monitor that indicates abnormal cardiac function or conduction that includes, but was not exclusive to:

    • Repaired or unrepaired coarctation.
    • Moderate or greater complexity congenital heart disease including tetralogy of Fallot, Atrioventricular septal defects, truncus arteriosus, total anomalous pulmonary venous return, double outlet right ventricle, or single ventricle heart disease.
  • ≥ 450 msec at the Screening Visit.
  • Known history or presence of condition that impacts hemodynamic stability (such as autonomic dysfunction and orthostatic intolerance).
  • Known history or presence of the following:

    • Chronic anemia (iron deficiency anemia that is resolved or adequately treated in the Investigator's opinion was allowed).
    • Chronic renal insufficiency ( \<60 mL/min/1.73 m2 for >3 months).
    • Chronic or recurrent illness that can affect hydration or volume status, including conditions associated with decreased nutritional intake or increased volume loss.
  • Known history or presence of malignant disease.
  • Participant with serum 25-hydroxy-vitamin D (25OHD) levels of \<30 nmol/L (\<12 ng/mL) at Screening Visit were excluded. Participants with 25OHD levels between 30-50 nmol/L (12-20 ng/mL) were randomized provided treatment with Vitamin D supplementation was initiated.
  • Any disease or condition that, in the opinion of the Investigator, may make the participant unlikely to fully complete the trial, may confound interpretation of trial results, or may present undue risk from receiving trial treatment. This included family situations, complications or manifestations, or medications that might impact safety or be considered confounding.
  • Sexually active male and female participants and female partners of male participants of not using a highly effective form of for the entire trial period and for 90 days after last dose of trial treatment.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    Navepegritide

    Participants received Navepegritide (TransCon CNP) 100 micrograms per kilogram (µg/kg) delivered once weekly by subcutaneous injection for a treatment period of up to 52 weeks.

    Drug: Navepegritide (TransCon CNP)

  • Placebo comparator
    Placebo for Navepegritide

    Participants received placebo matched for Navepegritide (TransCon CNP) 100 µg/kg delivered once weekly by subcutaneous injection for a treatment period of up to 52 weeks.

    Drug: Placebo for Navepegritide (TransCon CNP)

  • Experimental
    Open-Label Extension Period: Navepegritide

    Participants who completed the 52-week treatment period continued into the open-label extension period and received treatment with navepegritide (TransCon CNP) doses up to Week 104. All participants received navepegritide at a dose of 100 μg/kg/week.

    Drug: Navepegritide (TransCon CNP)

Interventions

  • Once-weekly subcutaneous injection of 100 µg/kg Navepegritide (TransCon CNP)

  • DrugPlacebo for Navepegritide (TransCon CNP)

    Once-weekly subcutaneous injection of 100 µg/kg placebo for Navepegritide (TransCon CNP)

06

What researchers measure

Primary outcomes

  1. Annualized Growth Velocity (AGV) at Week 52

    Annualized growth velocity is defined as (height - baseline height)/(date of height assessment - date of baseline) \* 365.25. Annualized growth velocity reported in terms of centimeters (cm) per year. Missing values at Week 52 were imputed by a multiple imputation method.

    Time frame: At Week 52

Secondary outcomes

  1. Change From Baseline in Height Z-score (ACH-specific) at Week 52

    ACH specific Z-scores of height provide a measure of growth relative to other individuals with ACH from the CLARITY database. A height Z-score is a standardized height measure after considering important factors like age and gender. Z-scores (or standard deviation scores) describe how far the measurement deviates from the mean. A height Z-score of 0 indicates that height is equal to the mean in the reference population. Negative numbers indicate values below the mean and positive numbers indicate values above the mean.

    Time frame: Baseline, Week 52

  2. Change From Baseline in Height Z-score (CDC-Based) at Week 52

    Z-scores of height are determined using Centers for Disease Control and Prevention (CDC) clinical growth charts for children. A height Z-score is a standardized height measure after considering important factors like age and gender. Z-scores (or standard deviation scores) describe how far the measurement deviates from the median. A height Z-score of 0 indicates that height is equal to the median in the reference population. Negative numbers indicate values below the median and positive numbers indicate values above the median.

    Time frame: Baseline, Week 52

07

Results

Posted Jul 14, 2026

Participant flow

Double-Blind Period (Up to Week 52)
Participant flow — Double-Blind Period (Up to Week 52)
MilestoneNavepegritidePlacebo for NavepegritideOpen-Label Extension Period: Navepegritide
Started57270
Completed55270
Not completed200
Withdrew: Withdrawal by parent/guardian200
OLE Period (From Week 52 up to Week 104)
Participant flow — OLE Period (From Week 52 up to Week 104)
MilestoneNavepegritidePlacebo for NavepegritideOpen-Label Extension Period: Navepegritide
Started0082
Completed0080
Not completed002
Withdrew: Lost to follow-up001
Withdrew: Withdrawal by parent/guardian001

Outcome measures

PrimaryAnnualized Growth Velocity (AGV) at Week 52

Annualized growth velocity is defined as (height - baseline height)/(date of height assessment - date of baseline) \* 365.25. Annualized growth velocity reported in terms of centimeters (cm) per year. Missing values at Week 52 were imputed by a multiple imputation method.

Time frame:
At Week 52
Reported as:
Least squares mean · centimeters per year
Annualized Growth Velocity (AGV) at Week 52
centimeters per yearNavepegritidePlacebo for Navepegritide
Annualized Growth Velocity (AGV) at Week 525.89 (5.66 to 6.13)4.41 (4.04 to 4.77)
Statistical analysis
  • Navepegritide vs Placebo for Navepegritide · ANCOVA · p = <0.0001 · Least square mean difference: 1.49 · 95% CI 1.05 to 1.93The ANCOVA model included treatment, stratification factor, baseline age, and baseline ACH-specific height Z-score as covariates.
SecondaryChange From Baseline in Height Z-score (ACH-specific) at Week 52

ACH specific Z-scores of height provide a measure of growth relative to other individuals with ACH from the CLARITY database. A height Z-score is a standardized height measure after considering important factors like age and gender. Z-scores (or standard deviation scores) describe how far the measurement deviates from the mean. A height Z-score of 0 indicates that height is equal to the mean in the reference population. Negative numbers indicate values below the mean and positive numbers indicate values above the mean.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · Z-score
Change From Baseline in Height Z-score (ACH-specific) at Week 52
Z-scoreNavepegritidePlacebo for Navepegritide
Change From Baseline in Height Z-score (ACH-specific) at Week 520.30 (0.24 to 0.35)0.01 (-0.07 to 0.10)
SecondaryChange From Baseline in Height Z-score (CDC-Based) at Week 52

Z-scores of height are determined using Centers for Disease Control and Prevention (CDC) clinical growth charts for children. A height Z-score is a standardized height measure after considering important factors like age and gender. Z-scores (or standard deviation scores) describe how far the measurement deviates from the median. A height Z-score of 0 indicates that height is equal to the median in the reference population. Negative numbers indicate values below the median and positive numbers indicate values above the median.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · Z-score
Change From Baseline in Height Z-score (CDC-Based) at Week 52
Z-scoreNavepegritidePlacebo for Navepegritide
Change From Baseline in Height Z-score (CDC-Based) at Week 520.15 (0.05 to 0.25)-0.15 (-0.27 to -0.03)

Adverse events

Collected over From Week 0 to Week 52 for double-blind treatment period and from Week 52 up to Week 104 for the Open Label Extension period (OLE) period. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Navepegritide0/57 (0%)3/57 (5.3%)52/57 (91.2%)
Placebo for Navepegritide0/27 (0%)3/27 (11.1%)25/27 (92.6%)
Open-Label Extension Period: Navepegritide0/82 (0%)0/82 (0%)71/82 (86.6%)
Most frequent serious events
Most frequent serious events
EventNavepegritidePlacebo for NavepegritideOpen-Label Extension Period: Navepegritide
Muscle spasmsMusculoskeletal and connective tissue disorders0/571/270/82
Mesenteric lymphadenitisBlood and lymphatic system disorders0/571/270/82
Sleep apnoea syndromeRespiratory, thoracic and mediastinal disorders0/571/270/82
TorticollisMusculoskeletal and connective tissue disorders1/570/270/82
Vertebral foraminal stenosisMusculoskeletal and connective tissue disorders1/570/270/82
Localised infectionInfections and infestations1/570/270/82
Most frequent other events
Showing 10 of 43
Most frequent other events
EventNavepegritidePlacebo for NavepegritideOpen-Label Extension Period: Navepegritide
NasopharyngitisInfections and infestations18/5710/2723/82
PyrexiaGeneral disorders20/576/2717/82
Otitis mediaInfections and infestations14/577/2717/82
Upper respiratory tract infectionInfections and infestations11/573/2711/82
VomitingGastrointestinal disorders11/573/277/82
HeadacheNervous system disorders10/573/2711/82
CoughRespiratory, thoracic and mediastinal disorders6/574/274/82
Sleep apnoea syndromeRespiratory, thoracic and mediastinal disorders8/573/273/82
Ear infectionInfections and infestations7/571/273/82
FallInjury, poisoning and procedural complications7/573/277/82

Baseline characteristics

Analysis was performed on full analysis set that included all randomized participants who have received at least one dose of investigational medicinal product (IMP) and have a non-missing baseline height as well as at least one post-baseline height measurement.

Age, Continuous
Age, Continuous(years)NavepegritidePlacebo for NavepegritideTotal
Mean5.56 ± 2.6085.95 ± 2.7485.68 ± 2.644
Sex: Female, Male
Sex: Female, Male(Participants)NavepegritidePlacebo for NavepegritideTotal
Female261339
Male311445
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)NavepegritidePlacebo for NavepegritideTotal
Hispanic or Latino516
Not Hispanic or Latino522577
Unknown or Not Reported011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)NavepegritidePlacebo for NavepegritideTotal
American Indian or Alaska Native000
Asian448
Native Hawaiian or Other Pacific Islander000
Black or African American000
White522274
More than one race112
Unknown or Not Reported000
Height
Height(centimeter)NavepegritidePlacebo for NavepegritideTotal
Mean88.82 ± 12.87189.10 ± 11.45088.98 ± 12.363
CDC-Based Height Z-score
CDC-Based Height Z-score(Z-score)NavepegritidePlacebo for NavepegritideTotal
Median-4.87 ± 0.976-5.24 ± 0.932-5.02 ± 0.968
Achondroplasia (ACH)-specific Height Z-score
Achondroplasia (ACH)-specific Height Z-score(Z-score)NavepegritidePlacebo for NavepegritideTotal
Mean0.18 ± 0.921-0.11 ± 0.7250.09 ± 0.869
08

Study locations

10 sites
  • Ascendis Pharma Investigational Site
    Saint Paul, Minnesota 55102, United States
  • Ascendis Pharma Investigational Site
    Columbia, Missouri 65212, United States
  • Ascendis Pharma Investigational Site
    Houston, Texas 77030, United States
  • Ascendis Pharma Investigational Site
    Madison, Wisconsin 53705, United States
  • Ascendis Pharma Investigational Site
    Parkville, 3052, Australia
  • Ascendis Pharma Investigational Site
    Montreal, H3T 1CS, Canada
  • Ascendis Pharma Investigational Site
    Copenhagen, 2100, Denmark
  • Ascendis Pharma Investigational Site
    Dublin, D01 YC76, Ireland
  • Ascendis Pharma Investigational Site
    Auckland, 1023, New Zealand
  • Ascendis Pharma Investigational Site
    Vitoria-Gasteiz, 1008, Spain
09

References and documents

Publications

  • McDonnell CM, Irving M, Nolting LA, Abdelrahman SG, Dalby LW, Ikle JM, Jensen SM, Komirenko AS, Ominsky MS, Shu AD, Hove HB. Navepegritide combined with lonapegsomatropin for the treatment of children with achondroplasia: 52-week results from the phase 2 COACH trial. Eur J Endocrinol. 2026 Jun 1;194(6):745-755. doi: 10.1093/ejendo/lvag082. PubMed 42144862 ↗
  • Savarirayan R, McDonnell C, Bacino CA, Hoernschemeyer DG, Legare JM, Abuzzahab MJ, Hofman PL, Campeau PM, de Bergua Domingo JM, Ward LM, Smit K, Smith A, Mao M, Ominsky MS, Freiberg LC, Shu AD, Hove HB. Once-Weekly Navepegritide in Children With Achondroplasia: The APPROACH Randomized Clinical Trial. JAMA Pediatr. 2026 Jan 1;180(1):18-25. doi: 10.1001/jamapediatrics.2025.4771. PubMed 41247754 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Not planned

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2023 to primary completion in Aug 2024, 17 months.

Results were first posted in Jul 2026, 1 year 11 months after primary completion. A results delay was requested in Aug 2025.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2022
First posted
Oct 28, 2022
StartActual
Mar 3, 2023
Primary completionActual
Aug 9, 2024
CompletionActual
Aug 13, 2025
Results delay requested
Aug 6, 2025
Results first posted
Jul 14, 2026
Last update
Jul 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05598320
Lead sponsor
Ascendis Pharma Growth Disorders A/S
Responsible party
Sponsor
First posted
Oct 28, 2022
Start date
Mar 3, 2023
Primary completion
Aug 9, 2024
Completion
Aug 13, 2025
Results posted
Jul 14, 2026
Last update
Jul 14, 2026

Study contacts

Medical Director, MD
study director · Ascendis Pharma A/S

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Navepegritide

Start the discussion